Akari Therapeutics, Plc (AKTX)
- Previous Close
1.1800 - Open
1.1300 - Bid --
- Ask --
- Day's Range
1.1300 - 1.2350 - 52 Week Range
1.0780 - 5.5000 - Volume
4,709 - Avg. Volume
11,664 - Market Cap (intraday)
9.588M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0400 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
80.00
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
www.akaritx.comRecent News: AKTX
Performance Overview: AKTX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AKTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AKTX
Valuation Measures
Market Cap
9.35M
Enterprise Value
5.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.07
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.33
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-115.51%
Return on Equity (ttm)
-1,281.43%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.01M
Diluted EPS (ttm)
-2.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
3.85M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-16.74M